Verastem, Inc.
VSTM Real Time Price USDRecent trades of VSTM by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by VSTM's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Solid forms of a dual raf/mek inhibitor Jan. 16, 2024
-
Patent Title: Therapeutic compositions, combinations, and methods of use Jan. 31, 2023
-
Patent Title: Therapeutic compositions, combinations, and methods of use Jan. 14, 2020
-
Patent Title: Methods and compositions for treating abnormal cell growth Sep. 10, 2019
-
Patent Title: Methods and compositions for treating abnormal cell growth May. 08, 2018
-
Patent Title: Synthesis and use of kinase inhibitors Nov. 29, 2016
-
Patent Title: Oral formulations of kinase inhibitors Jun. 28, 2016
-
Patent Title: Pyrimidine substituted purine compounds as kinase (s) inhibitors Sep. 22, 2015
-
Patent Title: Pyrimidine substituted purine compounds as kinase (s) inhibitors Jun. 17, 2014
-
Patent Title: Pyrimidine derivatives for the treatment of abnormal cell growth May. 13, 2014
-
Patent Title: Pyrimidine substituted purine derivatives Dec. 17, 2013
-
Patent Title: Pyrimidine substituted purine derivatives Aug. 21, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of VSTM in WallStreetBets Daily Discussion
Recent insights relating to VSTM
Recent picks made for VSTM stock on CNBC
ETFs with the largest estimated holdings in VSTM
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VSTM Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.